Two doses of the vaccine Pfizer/BioNTech They are effective in avoiding the risk of hospitalization for Covid-19 and all its variants for at least six months, according to a study published Tuesday in The Lancet.
The study by Pfizer and the US health network Kaiser Permanente analyzed the medical data of 3.4 million people in the southern state of California between December 4 and August 8.
WE RECOMMEND YOU: EU Authorizes Third Dose of Pfizer Vaccine for Seniors and High-Risk People
They found that the vaccine’s effectiveness against infection risks decreases over time, from 88% in the month following the second dose, to 44% after six months.
Secondly, the vaccine maintains its 90% efficacy against the risks of hospitalization due to covid-19, including delta variant infection, for at least six months, the study revealed.
The data confirm the results of previous estimates from the United States Centers for Disease Control and Prevention (CDC), the United States’ main federal public health agency, and Israel’s Ministry of Health, The Lancet said in a statement. .
Our study confirms that vaccines are a central tool to control the epidemic and are extremely effective in preventing severe forms and hospitalizations, including against delta and other worrisome variants, “Sara Tartof, lead author of the study, summarized in the statement.
Luis Jodar, vice president and chief medical officer of Pfizer, said that “a specific analysis of the variants clearly shows that the vaccine is effective against all types of variants.”
nerc
–
